Sangeeta Goswami, Deblina Raychaudhuri, Pratishtha Singh, Seanu Meena Natarajan, Yulong Chen, Candice Poon, Mercedes Hennessey, Aminah J Tannir, Jan Zhang, Swetha Anandhan, Brittany Parker Kerrigan, Marc D Macaluso, Zhong He, Sonali Jindal, Frederick F Lang, Sreyashi Basu, Padmanee Sharma
Glioblastoma (GBM) tumors are enriched in immune-suppressive myeloid cells and are refractory to immune checkpoint therapy (ICT). Targeting epigenetic pathways to reprogram the functional phenotype of immune-suppressive myeloid cells to overcome resistance to ICT remains unexplored. Single-cell and spatial transcriptomic analyses of human GBM tumors demonstrated high expression of an epigenetic enzyme-histone 3 lysine 27 demethylase (KDM6B)-in intratumoral immune-suppressive myeloid cell subsets...
October 2023: Nature Cancer